- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00643240
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
Phase I Open Label, Single Arm Escalation Trial to Evaluate the Biodistribution and Safety of BU-12 in Patients With Advanced Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
PURPOSE: This phase I trial is studying the best dose of yttrium Y 90-labeled monoclonal antibody BU-12 in treating patients with advanced relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- To determine the biodistribution of indium-111 BU-12 in patients with refractory CD19+ leukemia.
Secondary
- To determine the maximum tolerated dose of yttrium Y 90 anti-CD19 antibody BU-12
- Determine the human anti-mouse antibody (HAMA) response.
- To define, preliminarily, the antitumor activity of yttrium Y 90 anti-CD19 antibody BU-12.
OUTLINE: Patients receive yttrium Y 90 anti-CD19 antibody BU-12/indium-111 BU-12 IV over 60 minutes on day 0 and undergo whole-body imaging on days 0, 1, 3, 4, and 7. Patients also undergo blood collection and bone marrow biopsy periodically for dosimetry calculations and pharmacokinetics.
After completion of study treatment, patients are followed periodically for 2 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Histologically confirmed CD19-positive (> 25% by flow cytometry evaluation of bone marrow blasts) disease of 1 of the following types:
- Primary refractory or relapsed acute lymphoblastic leukemia (ALL) defined as persistent disease following a minimum of two different standard effective chemotherapy induction attempts at time of diagnosis or at relapse
- Chronic Lymphocytic leukemia (CLL) following blast crisis (≥15% bone marrow blasts following a minimum of one standard effective chemotherapy induction attempt)
- Human anti-mouse antibody (HAMA) must be negative
- Patients who have relapsed ≥ 60 days following an autologous or allogeneic transplant are eligible if all other eligibility criteria are met
- No active central nervous system (CNS) disease
- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
- Life expectancy > 8 weeks
- Total bilirubin ≤ 2.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- LVEF ≥ 45% by MUGA/ECHO
- Oxygen saturation on room air > 92% and no oxygen requirement
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients mus use effective contraception
Exclusion criteria:
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to of yttrium Y 90 anti-CD19 antibody BU-12 or other agents used in study
Uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study requirements
- HIV-positive
- Active graft-vs-host disease
- Less than 4 weeks since prior agents and recovered
- Less than 7 days since prior therapy with any biologic agent, defined as a growth factor or cytokine
- Less than 3 months since prior antibody or biologic anticancer therapy (e.g., alemtuzumab or epratuzumab)
- Other concurrent investigational agents
- Patients with peripheral blasts > 5,000/uL may receive concurrent hydroxyurea
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 111 In-BU-12
111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
|
Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
Andere namen:
Patients receive indium-111 BU-12 IV over 60 minutes on day 0
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Biodistribution of indium-111 BU-12
Tijdsspanne: Immediately post infusion, 4-6 hours after infusion and Days 1, 3, 4 and 7 after infusion
|
Perform a whole body scan acquiring both anterior and posterior images at a speed of 10 cm/min (20 minute scan) using a medium energy collimator, a 256 x 1024 computer acquisition matrix and acquisition photo peak settings of 172 and 247 keV with 15% windows.
|
Immediately post infusion, 4-6 hours after infusion and Days 1, 3, 4 and 7 after infusion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Maximum tolerated dose of yttrium Y 90 anti-CD19 antibody BU-12
Tijdsspanne: Beginning Day 1 of treatment
|
DLT will be defined as bone marrow aplasia > 6 weeks duration from the first treatment day; specifically, failure to recover peripheral ANC > 500/μL and platelets > 20,000/μL documented by bone marrow aplasia, not malignant infiltration - Any NCI CTCAE v 3.0 grade 3 non-hematologic toxicity except for allergic reactions to radiolabeled BU-12 will be dose limiting.
If the BU-12 antibody is very allergenic, then ≥ grade 3 allergic reactions will be dose limiting.
|
Beginning Day 1 of treatment
|
Presence or absence of a human antibody to murine antibody
Tijdsspanne: baseline, 28 and 60 days post therapy, and at 6 months post therapy
|
Presence or absence of a human antibody to murine antibody at baseline, 28 and 60 days post therapy, and at 6 months post therapy
|
baseline, 28 and 60 days post therapy, and at 6 months post therapy
|
Number of Patients by Clinical Response
Tijdsspanne: day 28 and day 60
|
Patients evaluable for DLT will be assessed for response at day 28 and day 60 post therapy dose (event is whether or not the patient has a Complete Remission, Partial Remission, Stable Disease, Refractory Disease, Relapsed Disease).
The proportion of patients by disease status will be reported.
|
day 28 and day 60
|
Time to Clinical Response
Tijdsspanne: Day 28, 60, 6 Months
|
Time-to-event will be measured from date of therapy dose.
|
Day 28, 60, 6 Months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Brenda Weigel, MD, Masonic Cancer Center, University of Minnesota
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Leukemie, Lymfoïde
- Leukemie
- Voorlopercel lymfoblastische leukemie-lymfoom
- Fysiologische effecten van medicijnen
- Immunologische factoren
- Antilichamen
- Antilichamen, monoklonaal
Andere studie-ID-nummers
- 2006LS057
- MT2006-09 (Andere identificatie: Blood and Marrow Transplantation Program)
- UMN-0611M96887 (Andere identificatie: IRB, University of Minnesota)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op yttrium Y 90 anti-CD19 monoclonal antibody BU12
-
City of Hope Medical CenterNational Cancer Institute (NCI)VoltooidNiet-gespecificeerde volwassen solide tumor, protocolspecifiekVerenigde Staten
-
Mayo ClinicNational Cancer Institute (NCI)VoltooidAnn Arbor stadium I graad 1 folliculair lymfoom | Ann Arbor stadium I graad 2 folliculair lymfoom | Ann Arbor stadium III graad 1 folliculair lymfoom | Ann Arbor stadium III graad 2 folliculair lymfoom | Ann Arbor stadium IV graad 1 folliculair lymfoom | Ann Arbor stadium IV graad 2 folliculair... en andere voorwaardenVerenigde Staten
-
City of Hope Medical CenterNational Cancer Institute (NCI)Voltooid
-
Northwestern UniversityNational Cancer Institute (NCI)Voltooid
-
University of SouthamptonNIHR Clinical Research Facility, University Hospital Southampton NHS Foundation... en andere medewerkersBeëindigdMultipel myeloom en plasmacelneoplasmaVerenigd Koninkrijk
-
Beth Israel Deaconess Medical CenterVoltooid
-
Mayo ClinicNational Cancer Institute (NCI)VoltooidRecidiverend diffuus grootcellig lymfoom bij volwassenen | Recidiverend graad 1 folliculair lymfoom | Recidiverend graad 2 folliculair lymfoom | Recidiverend graad 3 folliculair lymfoom | Recidiverend mantelcellymfoom | Recidiverend marginale zone-lymfoom | Milt marginale zone lymfoom | Waldenström... en andere voorwaardenVerenigde Staten
-
University of California, DavisOnbekend
-
Chandrikha ChandrasekharanAstraZeneca; Biocompatibles UK LtdGeschorstGemetastaseerde colorectale kanker | Colorectale neoplasmata | Rectale kanker | Darmkanker | Colorectale kanker uitgezaaid | Levermetastasen | Colo-rectale kanker | Colorectaal carcinoom | Colorectaal adenocarcinoom | Levermetastase DarmkankerVerenigde Staten
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)BeëindigdRadio-embolisatie en ipilimumab bij de behandeling van patiënten met oogmelanoom met levermetastasenLevermetastasen | Ciliair lichaam en choroïde melanoom, middelgroot / groot formaat | Ciliair lichaam en choroïde melanoom, klein formaat | Iris melanoom | Gemetastaseerd intraoculair melanoom | Recidiverend intraoculair melanoom | Stadium IV intraoculair melanoom | Extraoculair ExtensiemelanoomVerenigde Staten